Teva Agrees To Suspend Sales Of Moexipril Pending Patent Suit Outcome
Teva said the suspension was part of an agreement reached with Schwarz. Under the agreement, Teva will suspend all manufacturing and sales of its Moexipril HCl tablets until the outstanding litigation at the New Jersey District Court is cleared up.
Teva began selling Moexipril tablets in two doses, 7.5 mg and...
To view the full article, register now.